Handa Pharmaceuticals, Inc. (TPEX:6620)

Market Cap	11.70B +13.3%
Revenue (ttm)	1.73B +108.2%
Net Income	749.77M +58.6%
EPS	4.83 +44.2%
Shares Out	165.53M
PE Ratio	14.64
Forward PE	n/a
Dividend	2.00 (2.83%)
Ex-Dividend Date	n/a

Volume	411,560
Average Volume	622,850
Open	70.20
Previous Close	70.70
Day's Range	69.70 - 70.70
52-Week Range	67.30 - 154.00
Beta	0.80
RSI	38.07
Earnings Date	May 14, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6620

Financial Performance

In 2025, Handa Pharmaceuticals's revenue was 1.73 billion, an increase of 108.17% compared to the previous year's 830.67 million. Earnings were 749.77 million, an increase of 58.60%.